Skip to content

Avalo Therapeutics AVTX Other operating expenses

Discontinued — last reported Q3 '19

Other operating expenses at other companies

Xencor logo
XencorXNCR
$82.38M+8.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$60.19M+8.8%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$65.83M-1.6%
Absci Corporation logo
Absci CorporationABSI
$31.06M+7.4%
Vera Therapeutics logo
Vera TherapeuticsVERA
$125.13M+119%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$151M+0.7%

Segments

By segment

See full
Reportable Segment$70K+16.7%

Other financials

Income statement

See full
Revenue$59.0K-69.3%
Gross profit$963.0K+8,855%
Operating income-$20.9M-42.5%
Net income-$19.6M-49.3%
EPS (diluted)-$0.98+21.6%

Balance sheet

See full
Cash & equivalents$25.3M-79.8%
Total debt$328.0K-59.1%
Total equity$68.3M-44.3%
Total assets$99.9M-27.9%

Cash flow

See full
Operating cash flow-$17.7M-87.1%
CapEx-
Free cash flow-$15.0M-444%

Valuation

See full
Market cap$946.18M+1,783%
Enterprise value$921.19M-1,342%
P/S1,892.4×+1,852×

Profitability

See full
Gross margin182%+176pp
Operating margin-15,536.1%-17,275pp
Net margin-7,965.8%-10,750pp
FCF margin-11,123.8%-13,374pp

Returns & leverage

See full
Return on equity-88.8%
Debt / equity0.0×
Current ratio7.7×-14.9×

Where this comes from

Reported directly by Avalo Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Avalo Therapeutics’s 10-Q, filed November 14, 2019, on SEC EDGAR. View the filing →

Questions, answered.

What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.